RayKnowChina Research Map
Shortlist

Zhengzhou University

郑州大学

ZhengzhouUniversity or health system

Hospitals that carry this university's name, added together, plus papers and trials that name only the university.

Research activity, not treatment quality. Not medical advice. How this works

Nasopharyngeal carcinoma

鼻咽癌
0.9%Leads under 1 in 100 of China's research papers on NPC ▼ from 1.6%

Led 22 of 2,375 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (23.4%).

Run this PubMed search

Open trials led
0
Research papers it led
22
Trials it led
1
Share of China's trials
0.2%
Share of the world's papers
0.7%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 2220242025: 112025
ThemesImmunotherapyRadiotherapy techniqueRecurrent / metastatic disease

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. First Affiliated Hospital of Zhengzhou University15
  2. Henan Provincial People's Hospital3
  3. Zhengzhou Central Hospital, Zhengzhou University2
  4. Henan Provincial Chest Hospital1
  5. Nanozyme Medical Center Counted in the group total1
  6. Henan Cancer Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. How enteral nutrition modes influence nasopharyngeal carcinoma survivors with late dysphagia after radiotherapy: a randomized controlled study.2024Supportive care in cancer : official journal of the Multinational Association of Supportive Care in CancerRCT
  2. Analysis of the clinical efficacy and safety of anti-PD-1 immune checkpoint inhibitors in locally advanced nasopharyngeal cancer.2024Cancer medicineFree full text
  3. A novel automated planning approach for multi-anatomical sites cancer in Raystation treatment planning system.2023Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB)
  4. Alterations in nasal airflow and air conditioning after endoscopic nasopharyngectomy for recurrent nasopharyngeal carcinoma: a pilot computational fluid dynamics study.2026Computer methods in biomechanics and biomedical engineering
  5. Prognostic value of sarcopenia in patients with nasopharyngeal carcinoma: a meta-analysis.2025Annals of medicineFree full text
Trials on ClinicalTrials.gov6
  1. A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid TumorsRecruitingNCT05956587Study sitePhase 2Start 2024-01
  2. Intermittent Oro-esophageal Tube Feeding in Late Dysphagia for Nasopharyngeal CarcinomaWithdrawnNCT06248879Lead sponsorN/AStart 2024-02
  3. A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal CarcinomaActive, not recruitingNCT05126719Study sitePhase 2Start 2023-04
  4. Health Outcomes of Nasopharyngeal Carcinoma Patients Three Years After Treatment by the AI-assisted Home Enteral Nutrition ManagementCompletedNCT06603909Study siteN/AStart 2021-01
  5. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCCStatus unknownNCT02915432Study sitePhase 1/Phase 2Start 2016-12
  6. Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal CancerStatus unknownNCT01074021Study sitePhase 3Start 2009-10

PubMed searchClinicalTrials.gov

Oesophageal squamous cell carcinoma

食管鳞状细胞癌
6.9%Leads about 1 in 14 of China's research papers on ESCC

Led 203 of 2,923 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.9%).

Run this PubMed search

Open trials led
10
Research papers it led
203
Trials it led
27
Share of China's trials
4.8%
Share of the world's papers
4.7%
Papers led per year
2021: 1120212022: 2220222023: 1120232024: 1120242025: 002025
ThemesMolecular markers & genomicsImmunotherapyNeoadjuvant & combined treatment

Over half of these papers are lab or animal studies.

Papers it led5
  1. Perioperative toripalimab plus neoadjuvant chemotherapy might improve outcomes in resectable esophageal cancer: an interim analysis of a phase III randomized clinical trial.2024Cancer communications (London, England)RCTFree full text
  2. A multicenter randomized, controlled clinical trial of adjuvant sintilimab for esophageal squamous cell carcinoma.2023Future oncology (London, England)RCT
  3. Comparative clinical studies of primary chemoradiotherapy versus S-1 and nedaplatin chemotherapy against stage IVb oesophageal squamous cell carcinoma: a multicentre open-label randomised controlled trial.2022BMJ openRCTFree full text
  4. Development and validation of MRI-based radiomics signatures models for prediction of disease-free survival and overall survival in patients with esophageal squamous cell carcinoma.2022European radiologyRCT
  5. The Sequence of Chemotherapy and Toripalimab Might Influence the Efficacy of Neoadjuvant Chemoimmunotherapy in Locally Advanced Esophageal Squamous Cell Cancer-A Phase II Study.2021Frontiers in immunologyRCTFree full text
Trials on ClinicalTrials.gov6
  1. Surgery vs. Radical Chemoradiotherapy for Esophageal SCC After Neoadjuvant ImmunochemotherapyRecruitingNCT07629817Lead sponsorPhase 3Start 2026-06
  2. A Phase III Study of First-line Anlotinib Combined With Benmelstobart in Patients With Advanced Esophageal Squamous Cell CarcinomaNot yet recruitingNCT07446335Lead sponsorPhase 3Start 2026-04
  3. Standardized MRI and Structured Reporting for Esophageal Squamous Cell CarcinomaNot yet recruitingNCT07769658Lead sponsorStart 2026-09
  4. Neoadjuvant Radiochemotherapy Combined With Cadonilizumab for Local Advanced Esophageal Squamous Cell CancerRecruitingNCT07016724Lead sponsorPhase 2Start 2024-08
  5. Nimotuzumab Combined With Sintilimab and Chemotherapy for Advanced Esophageal Squamous Cell CarcinomaRecruitingNCT06718205Lead sponsorPhase 2Start 2023-03
  6. Camrelizumab in Combination With Apatinib Mesylate Plus Short-course Chemotherapy for Advanced ESCCRecruitingNCT05738434Lead sponsorPhase 2Start 2023-03

PubMed searchClinicalTrials.gov

Hepatocellular carcinoma

肝细胞癌
1.9%Leads about 1 in 52 of China's research papers on HCC

Led 284 of 14,765 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (5.5%).

Run this PubMed search

Open trials led
3
Research papers it led
284
Trials it led
8
Share of China's trials
0.5%
Share of the world's papers
1.0%
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 2220242025: 002025
ThemesRecurrence & prognosisImmunotherapy & targeted drugsLocal treatment (ablation, TACE, HAIC)

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. First Affiliated Hospital of Zhengzhou University169
  2. Henan Cancer Hospital34
  3. Henan Provincial People's Hospital30
  4. Zhengzhou Central Hospital, Zhengzhou University Counted in the group total5
  5. Fifth Affiliated Hospital of Zhengzhou University Counted in the group total4
  6. Third Affiliated Hospital of Zhengzhou University Counted in the group total3

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Comparison of drug-eluting bead transarterial chemoembolization combined with apatinib versus drug-eluting bead transarterial chemoembolization for the treatment of unresectable hepatocellular carcinoma: a randomized, pr2024Signal transduction and targeted therapyRCTFree full text
  2. Transcatheter arterial chemoembolization using CalliSpheres beads loaded with arsenic trioxide for unresectable large or huge hepatocellular carcinoma: a prospective study.2024European radiologyRCT
  3. Machine Learning-Based Development of Nomogram for Hepatocellular Carcinoma to Predict Acute Liver Function Deterioration After Drug-Eluting Beads Transarterial Chemoembolization.2023Academic radiologyRCT
  4. Gastroesophageal junction cancer with hepatic metastasis: Effective Treatment using microsphere embolization combined with transarterial infusion chemotherapy.2021Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the LiverRCT
  5. Development of a circulating tumor DNA methylation biomarker panel for hepatocellular carcinoma detection.2026European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
Trials on ClinicalTrials.gov6
  1. A Prospective, Single-Arm, Open-Label Clinical Study of the Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Combined With Targeted Therapy and a PD-1 Inhibitor in Patients With Postoperative Hepatocellular Carcinoma and Microvascular InvasionNot yet recruitingNCT07790419Lead sponsorPhase 4Start 2026-08
  2. A Study of AK112, a PD-1/ VEGF Bispecific Antibody, for Resectable Hepatocellular Carcinoma With High Recurrence RiskRecruitingNCT06930573Lead sponsorPhase 4Start 2024-12
  3. Backline Treatment of Advanced Hepatocellular Carcinoma With PalbociclibRecruitingNCT06478927Lead sponsorN/AStart 2024-01
  4. MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)RecruitingNCT07479485Study sitePhase 1/Phase 2Start 2026-04
  5. GKL-006 Injection Plus TACE Versus TACE Alone in Patients With Unresectable Hepatocellular CarcinomaRecruitingNCT07209813Study sitePhase 2Start 2025-11
  6. A Study on the Heterogeneity of Efficacy of Interventional Therapy Combined With Systemic Therapy for Liver Cancer Based on Multi-center Real-world DataNot yet recruitingNCT07156617Study siteStart 2025-10

PubMed searchClinicalTrials.gov

Stomach cancer

胃癌
2.6%Leads about 1 in 38 of China's research papers on Stomach cancer ▲ from 2.0%

Led 255 of 9,782 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (3.9%).

Run this PubMed search

Open trials led
9
Research papers it led
255
Trials it led
27
Share of China's trials
1.8%
Share of the world's papers
1.2%
Papers led per year
2021: 0020212022: 2220222023: 2220232024: 1120242025: 002025
ThemesImaging & AIPeritoneal spread & advanced diseaseImmunotherapy & targeted drugs

Hospitals counted here

  1. First Affiliated Hospital of Zhengzhou University105
  2. Henan Cancer Hospital76
  3. Henan Provincial People's Hospital25
  4. Fifth Affiliated Hospital of Zhengzhou University11
  5. Zhengzhou Central Hospital, Zhengzhou University Counted in the group total3
  6. Third Affiliated Hospital of Zhengzhou University Counted in the group total2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. A randomized phase 2 study of HLX22 plus trastuzumab biosimilar HLX02 and XELOX as first-line therapy for HER2-positive advanced gastric cancer.2024Med (New York, N.Y.)RCT
  2. Comparison of MRI and CT-Based Radiomics and Their Combination for Early Identification of Pathological Response to Neoadjuvant Chemotherapy in Locally Advanced Gastric Cancer.2023Journal of magnetic resonance imaging : JMRIRCT
  3. Establishment and validation of a prognostic nomogram for postoperative patients with gastric cardia adenocarcinoma: A study based on the Surveillance, Epidemiology, and End Results database and a Chinese cohort.2023Cancer medicineRCT
  4. Application Value of the Diagnosis during Early Carcinoma of Upper Digestive Tract Based on Optical Enhanced Endoscopic Technique.2022Computational and mathematical methods in medicineRCTFree full text
  5. Prognostic and Predictive Model of the Log Odds of the Negative Lymph Node/T Stage Ratio in Resectable Gastric Adenocarcinoma Patients.2022Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary TractRCT
Trials on ClinicalTrials.gov6
  1. Retlirafusp Alfa Combined With Apatinib and Nab-Paclitaxel as Second-line Treatment for Gastric or Gastroesophageal Junction CancerNot yet recruitingNCT07610629Lead sponsorPhase 2Start 2026-05
  2. IBI363 Plus Bevacizumab With or Without Nab-Paclitaxel for Second-Line Treatment of Advanced Gastric CancerNot yet recruitingNCT07361991Lead sponsorPhase 1/Phase 2Start 2026-03
  3. PDL1/TGFβ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastric CancerRecruitingNCT07294664Lead sponsorPhase 2Start 2025-06
  4. A Random, Non-controlled, Open Clinical Study of Apatinib Mesylate Combined With Albumin-bound Paclitaxel ± Adebrelimab in Treating Advanced Second-line Gastric CancerRecruitingNCT07770113Lead sponsorPhase 2Start 2025-06
  5. RC48 Plus AK104 as First-line Treatment for HER2-overexpressing Advanced Gastric CancerNot yet recruitingNCT06492317Lead sponsorPhase 2Start 2024-07
  6. Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanced Gastric CancerRecruitingNCT07334431Lead sponsorPhase 1/Phase 2Start 2024-02

PubMed searchClinicalTrials.gov

Hepatoblastoma

肝母细胞瘤
1.9%Leads about 1 in 51 of China's research papers on Hepatoblastoma ▼ from 4.7%

Led 3 of 154 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (13.6%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.7%
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 1120242025: 002025

Hospitals counted here

  1. First Affiliated Hospital of Zhengzhou University2
  2. Third Affiliated Hospital of Zhengzhou University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Retinoblastoma

视网膜母细胞瘤
2.7%Leads about 1 in 38 of China's research papers on Retinoblastoma ▼ from 5.4%

Led 8 of 301 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (12.0%).

Run this PubMed search

Open trials led
0
Research papers it led
8
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.7%
Papers led per year
2021: 1120212022: 1120222023: 1120232024: 2220242025: 002025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. First Affiliated Hospital of Zhengzhou University5
  2. Henan Provincial People's Hospital2
  3. Children's Hospital, Zhengzhou University1
  4. Luoyang Central Hospital, Zhengzhou University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Chordoma

脊索瘤
1.9%Leads about 1 in 53 of China's research papers on Chordoma

Led 2 of 105 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (23.8%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 002025

Hospitals counted here

  1. Second Affiliated Hospital of Zhengzhou University2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Osteosarcoma

骨肉瘤
3.1%Leads about 1 in 32 of China's research papers on Osteosarcoma

Led 71 of 2,257 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
71
Trials it led
1
Share of China's trials
1.7%
Share of the world's papers
1.4%
Papers led per year
2021: 2220212022: 1120222023: 0020232024: 2220242025: 002025

Over half of these papers are lab or animal studies.

PubMed searchClinicalTrials.gov

Gastrointestinal stromal tumour

胃肠道间质瘤
1.7%Leads about 1 in 58 of China's research papers on Gastrointestinal stromal tumour

Led 9 of 523 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.3%).

Run this PubMed search

Open trials led
0
Research papers it led
9
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.5%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 4420242025: 112025

Hospitals counted here

  1. First Affiliated Hospital of Zhengzhou University8
  2. Henan Cancer Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Endoscopic versus laparoscopic resection of gastrointestinal stromal tumors at the esophagogastric junction using propensity score matching analysis.2025Scientific reports
  2. Appendiceal fecalith misdiagnosed as cecal stromal tumor: don't fall into the trap.2024Endoscopy
  3. Optimal management options for esophageal gastrointestinal stromal tumors (E-GIST).2024European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  4. Endoscopic resection of extra-luminal gastric gastrointestinal stromal tumors using a snare assisted external traction technique (with video).2024Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  5. Comparative Analysis of Enbloc or Piecemeal Removal After Enbloc Resection of Gastrointestinal Stromal Tumors.2024Digestive diseases and sciences
Trials on ClinicalTrials.gov2
  1. Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)RecruitingNCT07379047Study sitePhase 2/Phase 3Start 2026-05
  2. A Study of HQP1351 in Patients With GIST or Other Solid TumorsRecruitingNCT03594422Study sitePhase 1Start 2018-07

PubMed searchClinicalTrials.gov

Neuroblastoma

神经母细胞瘤
2.6%Leads about 1 in 38 of China's research papers on Neuroblastoma

Led 30 of 1,132 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.8%).

Run this PubMed search

Open trials led
0
Research papers it led
30
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.7%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 552025

Over half of these papers are lab or animal studies.

PubMed searchClinicalTrials.gov

Ewing sarcoma

尤文肉瘤
1.8%Leads about 1 in 54 of China's research papers on Ewing sarcoma ▼ from 2.4%

Led 3 of 163 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.6%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 1120242025: 112025

Hospitals counted here

  1. First Affiliated Hospital of Zhengzhou University3

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Multiple myeloma

多发性骨髓瘤
2.3%Leads about 1 in 43 of China's research papers on Myeloma

Led 39 of 1,676 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.8%).

Run this PubMed search

Open trials led
0
Research papers it led
39
Trials it led
3
Share of China's trials
0.6%
Share of the world's papers
0.4%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 332025
ThemesDiagnosis, MRD & riskRelapse & resistanceDrug combinations

Hospitals counted here

  1. Henan Cancer Hospital18
  2. First Affiliated Hospital of Zhengzhou University15
  3. Henan Provincial People's Hospital5
  4. Second Affiliated Hospital of Zhengzhou University Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Long-term follow-up of patients with relapsed/refractory multiple myeloma after BCMA CAR-T-cell therapy.2025Frontiers in immunologyFree full text
  2. Impact of type 2 and steroid-Induced diabetes mellitus on prognosis in patients with multiple myeloma.2025World journal of surgical oncologyFree full text
  3. Clinical characteristics and risk factors of infection in initially treated patients with multiple myeloma during the induction period.2025Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy
  4. Quantitative Analysis of Whole-Body MRI for Accessing the Degree of Diffuse Infiltration Patterns and Identifying High Risk Cases of Newly Diagnosed Multiple Myeloma.2024Journal of magnetic resonance imaging : JMRI
  5. High Red Blood Cell Distribution Width to Platelet Ratio is an Independent Poor Prognostic Factor in Patients with Newly Diagnosed Multiple Myeloma.2023Discovery medicine
Trials on ClinicalTrials.gov6
  1. Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma PatientsRecruitingNCT07663253Study siteStart 2026-06
  2. To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple MyelomaRecruitingNCT07454187Study sitePhase 1/Phase 2Start 2026-04
  3. Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT07569757Study sitePhase 3Start 2026-06
  4. A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Multiple Myeloma(LB2505-0001)Not yet recruitingNCT07399444Study siteEarly phase 1Start 2026-01
  5. A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple MyelomaRecruitingNCT07477587Study sitePhase 1Start 2026-05
  6. A Phase Ib/II Clinical Study on the Application of Linperlisib Combined with the VRD Regimen in Newly Diagnosed Patients with Multiple MyelomaNot yet recruitingNCT06799676Study sitePhase 1/Phase 2Start 2025-02

PubMed searchClinicalTrials.gov

B-cell acute lymphoblastic leukaemia (B-ALL)

B 细胞急性淋巴细胞白血病
0.9%Leads under 1 in 100 of China's research papers on B-ALL ▼ from 2.9%

Led 2 of 225 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.9%).

Run this PubMed search

Open trials led
1
Research papers it led
2
Trials it led
3
Share of China's trials
1.2%
Share of the world's papers
0.2%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 1120242025: 002025
ThemesStem cell transplantPhiladelphia chromosome & geneticsCAR-T & cell therapy

Hospitals counted here

  1. Henan Provincial People's Hospital Counted in the group total1
  2. First Affiliated Hospital of Zhengzhou University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Aplastic anaemia

再生障碍性贫血
3.4%Leads about 1 in 29 of China's research papers on Aplastic anaemia

Led 14 of 412 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (17.2%).

Run this PubMed search

Open trials led
0
Research papers it led
14
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.9%
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 2220242025: 112025
ThemesStem cell transplantChildrenClonal evolution & PNH

Hospitals counted here

  1. First Affiliated Hospital of Zhengzhou University9
  2. Henan Cancer Hospital4
  3. Henan Provincial People's Hospital Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Haemophagocytic lymphohistiocytosis (HLH)

噬血细胞性淋巴组织细胞增生症
1.2%Leads about 1 in 80 of China's research papers on HLH

Led 5 of 399 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (22.3%).

Run this PubMed search

Open trials led
0
Research papers it led
5
Trials it led
1
Share of China's trials
2.1%
Share of the world's papers
0.3%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 4420242025: 112025
ThemesEBV & infection triggersLymphoma & cancer-related HLHDiagnosis & prognosis

Hospitals counted here

  1. First Affiliated Hospital of Zhengzhou University3
  2. Henan Provincial People's Hospital Counted in the group total1
  3. Henan Cancer Hospital Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Haemophilia A

血友病 A
2.2%Leads about 1 in 45 of China's research papers on Haemophilia A

Led 6 of 272 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (15.8%).

Run this PubMed search

Open trials led
0
Research papers it led
6
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 1120212022: 1120222023: 1120232024: 0020242025: 222025

Hospitals counted here

  1. First Affiliated Hospital of Zhengzhou University3
  2. Henan Provincial People's Hospital2
  3. Henan Cancer Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. The prediction of haemophilic arthropathy progression based on MRI findings and clinical characteristics.2025Orphanet journal of rare diseases
  2. Sequential combined bypassing therapy in haemophilia patients with high titer inhibitors: surgical experience.2025Annals of hematology
  3. Acquired Hemophilia A: A Retrospective Multicenter Analysis of 42 Patients.2023Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  4. Delivery of Cas9-guided ABE8e into stem cells using poly(l-lysine) polypeptides for correction of the hemophilia-associated FIX missense mutation.2022Biochemical and biophysical research communications
  5. Mutation analysis in the F8 gene in 485 families with haemophilia A and prenatal diagnosis in China.2021Haemophilia : the official journal of the World Federation of Hemophilia
Trials on ClinicalTrials.gov6
  1. To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia ARecruitingNCT06833983Study sitePhase 3Start 2025-03
  2. Longitudinal Cohort of Thrombosis and Hemostasis DiseasesRecruitingNCT06727669Study siteStart 2024-11
  3. Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) as Prophylactic Treatment.Active, not recruitingNCT07684898Study sitePhase 3Start 2026-06
  4. Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) On-Demand TreatmentActive, not recruitingNCT07663903Study sitePhase 3Start 2026-04
  5. Safety and Efficacy of STSP-0601 in Adult Patients with Hemophilia a or B with InhibitorCompletedNCT06289166Study sitePhase 2Start 2024-03
  6. Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion ProteinCompletedNCT06142552Study sitePhase 3Start 2023-12

PubMed searchClinicalTrials.gov

Thrombotic thrombocytopenic purpura

血栓性血小板减少性紫癜
3.1%Leads about 1 in 32 of China's research papers on Thrombotic thrombocytopenic purpura ▼ from 4.3%

Led 2 of 64 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.4%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 112025

Hospitals counted here

  1. First Affiliated Hospital of Zhengzhou University1
  2. Henan Provincial People's Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Neuromyelitis optica spectrum disorder (NMOSD)

视神经脊髓炎谱系疾病
2.9%Leads about 1 in 35 of China's research papers on NMOSD ▲ from 1.1%

Led 14 of 485 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.5%).

Run this PubMed search

Open trials led
0
Research papers it led
14
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.8%
Papers led per year
2021: 3320212022: 1120222023: 0020232024: 0020242025: 112025
ThemesAntibodies & diagnosisAcute attack treatmentImaging

Hospitals counted here

  1. First Affiliated Hospital of Zhengzhou University11
  2. Henan Provincial People's Hospital2
  3. Fifth Affiliated Hospital of Zhengzhou University Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Myasthenia gravis

重症肌无力
2.8%Leads about 1 in 36 of China's research papers on Myasthenia gravis ▲ from 1.3%

Led 14 of 499 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.6%).

Run this PubMed search

Open trials led
0
Research papers it led
14
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.6%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 332025
ThemesAntibodies & diagnosisStandard immunotherapyThymus & thymectomy

Hospitals counted here

  1. First Affiliated Hospital of Zhengzhou University4
  2. Second Affiliated Hospital of Zhengzhou University3
  3. Henan Provincial People's Hospital2
  4. Luoyang Central Hospital, Zhengzhou University Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Moyamoya disease

烟雾病
4.8%Leads about 1 in 21 of China's research papers on Moyamoya ▲ from 1.8%

Led 17 of 356 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (19.9%).

Run this PubMed search

Open trials led
0
Research papers it led
17
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
1.4%
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 2220242025: 112025
ThemesImaging & blood flowStroke & bleeding outcomesRevascularisation surgery

Hospitals counted here

  1. First Affiliated Hospital of Zhengzhou University10
  2. Henan Provincial People's Hospital5
  3. Affiliated Tumor Hospital of Zhengzhou University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Wilson disease

肝豆状核变性(Wilson 病)
0.5%Leads under 1 in 100 of China's research papers on Wilson disease ▼ from 4.2%

Led 1 of 201 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (7.5%).

Run this PubMed search

Open trials led
0
Research papers it led
1
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.1%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025
ThemesGenetics (ATP7B)Treatment (chelation, zinc)Children

Hospitals counted here

  1. First Affiliated Hospital of Zhengzhou University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎
4.5%Leads about 1 in 22 of China's research papers on Anti-NMDA receptor encephalitis ▲ from 3.2%

Led 12 of 264 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.2%).

Run this PubMed search

Open trials led
0
Research papers it led
12
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
1.6%
Papers led per year
2021: 1120212022: 2220222023: 0020232024: 1120242025: 112025

Hospitals counted here

  1. First Affiliated Hospital of Zhengzhou University9
  2. Henan Provincial People's Hospital2
  3. Second Affiliated Hospital of Zhengzhou University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Idiopathic pulmonary fibrosis

特发性肺纤维化
1.8%Leads about 1 in 55 of China's research papers on Idiopathic pulmonary fibrosis ▼ from 3.0%

Led 18 of 989 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
18
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.5%
Papers led per year
2021: 1120212022: 1120222023: 1120232024: 0020242025: 222025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. First Affiliated Hospital of Zhengzhou University12
  2. Henan Provincial People's Hospital5

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Potential function exploration of lncRNAs in idiopathic pulmonary fibrosis: insights from whole transcriptome sequencing data analysis.2025Clinics (Sao Paulo, Brazil)
  2. Antidepressant intervention to possibly delay disease progression and frailty in elderly idiopathic pulmonary fibrosis patients: a clinical trial.2025Aging clinical and experimental research
  3. Multicenter Population Pharmacokinetics and Exposure-Efficacy Analysis of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis.2023Clinical pharmacokinetics
  4. Contribution of Adiponectin/Carnitine Palmityl Transferase 1A-Mediated Fatty Acid Metabolism during the Development of Idiopathic Pulmonary Fibrosis.2022Oxidative medicine and cellular longevity
  5. Efficacy and safety of pirfenidone in the treatment of idiopathic pulmonary fibrosis patients: a systematic review and meta-analysis of randomised controlled trials.2021BMJ open
Trials on ClinicalTrials.gov6
  1. Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)RecruitingNCT07687459Study sitePhase 3Start 2026-09
  2. A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary FibrosisRecruitingNCT07121413Study sitePhase 2Start 2025-11
  3. Menstrual Blood-Derived Mesenchymal Stem Cell Injection (SC01009) in the Treatment of Idiopathic Pulmonary FibrosisNot yet recruitingNCT07131150Study sitePhase 2Start 2025-08
  4. Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary FibrosisTerminatedNCT06097260Study sitePhase 2Start 2023-11
  5. Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT05938920Study sitePhase 2Start 2023-06
  6. A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary FibrosisTerminatedNCT04552899Study sitePhase 3Start 2021-03

PubMed searchClinicalTrials.gov

Lymphangioleiomyomatosis

肺淋巴管平滑肌瘤病
0.0%Leads none of China's research papers on Lymphangioleiomyomatosis

Led 0 of 45 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (31.1%).

Run this PubMed search

Open trials led
0
Research papers it led
0
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.0%

PubMed searchClinicalTrials.gov

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症
0.8%Leads under 1 in 100 of China's research papers on Amyotrophic lateral sclerosis ▼ from 1.6%

Led 6 of 779 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.3%).

Run this PubMed search

Open trials led
0
Research papers it led
6
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.09%
Papers led per year
2021: 2220212022: 1120222023: 0020232024: 2220242025: 002025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. First Affiliated Hospital of Zhengzhou University5
  2. Henan Provincial People's Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Spinal muscular atrophy

脊髓性肌萎缩症
0.0%Leads none of China's research papers on Spinal muscular atrophy

Led 0 of 55 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (29.1%).

Run this PubMed search

Open trials led
0
Research papers it led
0
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.0%

PubMed searchClinicalTrials.gov

Fabry disease

法布雷病
0.0%Leads none of China's research papers on Fabry disease

Led 0 of 73 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (12.3%).

Run this PubMed search

Open trials led
0
Research papers it led
0
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.0%
Trials on ClinicalTrials.gov2
  1. Study of the Safety and Biologic Activity of AL01211 in Treatment Naive Males With Classic Fabry DiseaseStatus unknownNCT06114329Study sitePhase 2Start 2023-10
  2. Fabry Aim Children Early (ACE) ProjectWithdrawnNCT04965467Study siteStart 2021-07

PubMed searchClinicalTrials.gov

Duchenne muscular dystrophy

杜氏肌营养不良
4.7%Leads about 1 in 21 of China's research papers on Duchenne muscular dystrophy

Led 10 of 213 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.8%).

Run this PubMed search

Open trials led
0
Research papers it led
10
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 332025

PubMed searchClinicalTrials.gov

Behçet disease

白塞病
3.7%Leads about 1 in 27 of China's research papers on Behçet disease New since 2021

Led 9 of 245 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (22.9%).

Run this PubMed search

Open trials led
0
Research papers it led
9
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.7%
Papers led per year
2021: 2220212022: 0020222023: 1120232024: 2220242025: 002025

Hospitals counted here

  1. First Affiliated Hospital of Zhengzhou University9

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

IgA nephropathy

IgA 肾病
4.9%Leads about 1 in 20 of China's research papers on IgA nephropathy

Led 36 of 736 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.4%).

Run this PubMed search

Open trials led
0
Research papers it led
36
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
2.1%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 332025

Hospitals counted here

  1. First Affiliated Hospital of Zhengzhou University35
  2. Henan Provincial People's Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Primary biliary cholangitis

原发性胆汁性胆管炎
0.7%Leads under 1 in 100 of China's research papers on Primary biliary cholangitis

Led 2 of 300 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (12.0%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 112025

Hospitals counted here

  1. First Affiliated Hospital of Zhengzhou University2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Inherited epidermolysis bullosa

遗传性大疱性表皮松解症
5.4%Leads about 1 in 19 of China's research papers on Inherited epidermolysis bullosa New since 2021

Led 3 of 56 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (12.5%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 0020242025: 112025

Hospitals counted here

  1. Henan Provincial People's Hospital2
  2. Second Affiliated Hospital of Zhengzhou University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Familial adenomatous polyposis

家族性腺瘤性息肉病
3.4%Leads about 1 in 29 of China's research papers on Familial adenomatous polyposis New since 2021

Led 2 of 59 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.2%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 112025

Hospitals counted here

  1. Henan Cancer Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Leber hereditary optic neuropathy

Leber 遗传性视神经病变
9.6%Leads about 1 in 10 of China's research papers on Leber hereditary optic neuropathy ▲ from 2.4%

Led 5 of 52 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (21.1%).

Run this PubMed search

Open trials led
0
Research papers it led
5
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
1.6%
Papers led per year
2021: 2220212022: 1120222023: 1120232024: 0020242025: 112025

Hospitals counted here

  1. Henan Provincial People's Hospital3
  2. First Affiliated Hospital of Zhengzhou University2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov